Cargando…

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and high mortality rates, mostly due to severe acute respiratory failure and multi-organ failure. Excessive and uncontrolled release of proinfla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botta, Cirino, Indrieri, Alessia, Garofalo, Eugenio, Biamonte, Flavia, Bruni, Andrea, Pasqua, Pino, Cesario, Francesco, Costanzo, Francesco Saverio, Longhini, Federico, Mendicino, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819896/ https://www.ncbi.nlm.nih.gov/pubmed/33489899 http://dx.doi.org/10.3389/fonc.2020.599502

Ejemplares similares

Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria region (Italy): A retrospective study
por: Bruni, Andrea, et al.
Publicado: (2022)

Bivalirudin vs. Enoxaparin in Intubated COVID-19 Patients: A Pilot Multicenter Randomized Controlled Trial
por: Garofalo, Eugenio, et al.
Publicado: (2022)

Avoiding complications during prone position ventilation
por: Bruni, Andrea, et al.
Publicado: (2021)

Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: An exploratory study
por: Garofalo, Eugenio, et al.
Publicado: (2023)

HiJAKing Innate Lymphoid Cells?
por: Sciumè, Giuseppe, et al.
Publicado: (2017)

HiJAKing Immunotherapy-Resistant Melanoma for a Cure
por: Shi, Lewis Zhichang, et al.
Publicado: (2023)

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
por: Elli, Elena Maria, et al.
Publicado: (2019)

β-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
por: Melchiori, Luca, et al.
Publicado: (2010)

Current Practice of High Flow through Nasal Cannula in Exacerbated COPD Patients
por: Bruni, Andrea, et al.
Publicado: (2022)

Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response
por: Sacco, Alessandro, et al.
Publicado: (2021)

Benefits of secretion clearance with high frequency percussive ventilation in tracheostomized critically ill patients: a pilot study
por: Garofalo, Eugenio, et al.
Publicado: (2023)

An Observational Study With the Janssen Autism Knowledge Engine (JAKE(®)) in Individuals With Autism Spectrum Disorder
por: Ness, Seth L., et al.
Publicado: (2019)

Jake, Leon O. Jacobson, M.D.: The Life and Work of a Distinguished Medical Scientist
por: Kim, Jane N.
Publicado: (2007)

JAKE® Multimodal Data Capture System: Insights from an Observational Study of Autism Spectrum Disorder
por: Ness, Seth L., et al.
Publicado: (2017)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility
por: Biamonte, Flavia, et al.
Publicado: (2021)

Should high-flow through nasal cannula be used during bronchoscopy in critically ill patients with hypoxemic acute respiratory failure?
por: Longhini, Federico, et al.
Publicado: (2021)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
por: Botta, Cirino, et al.
Publicado: (2020)

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
por: Breccia, Massimo, et al.
Publicado: (2019)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

Aggregometry and thromboelastography to identify the timing to trach a COVID‐19 patient receiving both antiplatelet therapy and enoxaparin
por: Tescione, Marco, et al.
Publicado: (2021)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Oxygenation strategies during flexible bronchoscopy: a review of the literature
por: Pelaia, Corrado, et al.
Publicado: (2021)

Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma
por: Battaglia, Anna Martina, et al.
Publicado: (2023)

How to avoid the perfect storm: The role of energy and photovoltaics
por: Fermeglia, Maurizio, et al.
Publicado: (2020)

Additional flight delays and magnetospheric–ionospheric disturbances during solar storms
por: Wang, Y., et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Mechanical ventilation weaning issues can be counted on the fingers of just one hand: part 1
por: Vetrugno, Luigi, et al.
Publicado: (2020)

Monitoring the patient–ventilator asynchrony during non-invasive ventilation
por: Longhini, Federico, et al.
Publicado: (2023)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

New setting of neurally adjusted ventilatory assist for noninvasive ventilation by facial mask: a physiologic study
por: Longhini, Federico, et al.
Publicado: (2017)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin
por: Alunno, Alessia, et al.
Publicado: (2020)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3e38ljbfa6mq403o8rtdaltua7